^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer

Excerpt:
Afatinib response was associated with coamplification of EGFR and ERBB2….Analysis of patients with ERBB2-amplified, trastuzumab-resistant EG cancer who were treated with the HER kinase inhibitor afatinib revealed that sensitivity and resistance to therapy were associated with EGFR/ERBB2 coamplification and MET amplification, respectively.
DOI:
10.1158/2159-8290